Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
Vaxart filed its definitive proxy statement for the July 16, 2026 Annual Meeting, urging shareholders to vote for its six director nominees on the white proxy card. The company highlights a contested election, warning against dissident shareholder nominees who it claims lack relevant biotech expertise and could disrupt clinical execution.
Key figures
- Barda funding value
- $453 million
- Director tenure avg
- 2.3 years
- Share purchase agreement
- $25 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.